Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E119.87 EPS (ttm)1.27 Insider Own1.00% Shs Outstand197.83M Perf Week4.68%
Market Cap30.12B Forward P/E28.30 EPS next Y5.38 Insider Trans0.87% Shs Float195.96M Perf Month1.65%
Income252.90M PEG3.91 EPS next Q1.26 Inst Own97.30% Short Float1.82% Perf Quarter8.16%
Sales1.55B P/S19.41 EPS this Y-0.80% Inst Trans-0.18% Short Ratio1.83 Perf Half Y43.78%
Book/sh12.00 P/B12.69 EPS next Y19.93% ROA8.50% Target Price190.95 Perf Year66.03%
Cash/sh7.66 P/C19.88 EPS next 5Y30.69% ROE11.20% 52W Range87.01 - 185.43 Perf YTD14.56%
Dividend- P/FCF64.34 EPS past 5Y44.70% ROI10.20% 52W High-16.04% Beta0.65
Dividend %- Quick Ratio3.60 Sales past 5Y43.00% Gross Margin89.10% 52W Low78.93% ATR7.74
Employees1774 Current Ratio3.80 Sales Q/Q37.90% Oper. Margin37.10% RSI (14)50.32 Volatility4.15% 5.35%
OptionableYes Debt/Eq0.05 EPS Q/Q-125.00% Profit Margin16.30% Rel Volume1.62 Prev Close152.23
ShortableYes LT Debt/Eq0.03 EarningsApr 24 BMO Payout0.00% Avg Volume1.95M Price155.69
Recom2.00 SMA204.25% SMA50-5.50% SMA20018.36% Volume3,057,131 Change2.27%
11-Mar-14Reiterated UBS Buy $185 → $202
11-Mar-14Reiterated Stifel Buy $207 → $219
06-Mar-14Reiterated Barclays Overweight $181 → $193
10-Feb-14Reiterated Deutsche Bank Buy $125 → $205
31-Jan-14Reiterated Stifel Buy $138 → $207
31-Jan-14Reiterated Canaccord Genuity Buy $161 → $200
31-Jan-14Reiterated Barclays Overweight $141 → $181
30-Jan-14Reiterated Brean Capital Buy $142 → $200
10-Jan-14Reiterated Barclays Overweight $127 → $141
06-Jan-14Reiterated UBS Buy $130 → $150
06-Jan-14Reiterated Canaccord Genuity Buy $138 → $161
25-Oct-13Reiterated Stifel Buy $131 → $138
25-Oct-13Reiterated Barclays Overweight $121 → $127
26-Jul-13Reiterated Barclays Overweight $118 → $121
26-Apr-13Reiterated UBS Buy $120 → $123
24-Sep-12Reiterated Canaccord Genuity Buy $115 → $132
25-Apr-12Reiterated Canaccord Genuity Buy $95 → $100
25-Apr-12Reiterated Barclays Overweight $84 → $104
26-Mar-12Initiated Canaccord Genuity Buy $95
23-Feb-12Upgrade UBS Neutral → Buy $73 → $99
24-Apr-14 02:32PM  Celgene Beats on First-Quarter Earnings: What's Next? at Motley Fool
02:23PM  Alexion Pharmaceuticals: How to Buck a Biotech Selloff at Barrons.com
01:02PM  3 Stocks Advancing The Drugs Industry at TheStreet
12:11PM  Nasdaq Leads As Indexes Reverse Upward at Investor's Business Daily
11:39AM  Alexion, Celgene Report Contrasting Q1 Earnings at Investor's Business Daily
11:02AM  Today's Top Health Care Stocks to Watch: AstraZeneca plc, Alexion Pharmaceuticals, Celgene Corporation and Novartis AG at Motley Fool
10:00AM  Alexion Pharmaceuticals, Inc. Earnings Call scheduled for 10:00 am ET today CCBN
09:49AM  Alexion Pharmaceuticals, Inc. Earnings Call scheduled for 10:00 am ET today CCBN
09:48AM  Alexion Pharmaceuticals (ALXN) Is Today's Momo Momentum Stock at TheStreet
07:07AM  Q1 2014 Alexion Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
06:30AM  Alexion Reports First Quarter 2014 Results Business Wire
06:15AM  Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica (NMO) and Refractory Generalized Myasthenia Gravis (MG) Business Wire
23-Apr-14 01:55PM  Why Biogen (BIIB) Stock Is Down Today at TheStreet
11:37AM  Biotech ETF Loses Ground as Earnings Disappoint at Barrons.com
11:00AM  Strong Q1 Earnings at Gilead on Stellar Sovaldi Sales Zacks
10:04AM  [video] Tech & biotech plays for your portfolio at CNBC
07:31AM  Alliance Fiber Optic, Talisman Energy, Gilead Sciences, Biogen Idec and Alexion Pharmaceuticals highlighted as Zacks Bull and Bear of the Day Zacks
06:37AM  Alexion's Soliris granted Orphan Drug Designation by European Commission theflyonthewall.com
06:30AM  European Commission Grants Orphan Drug Designation to SolirisĀ® (Eculizumab) for the Prevention of Graft Rejection Following Solid Organ Transplantation Business Wire
22-Apr-14 01:07PM  [video] Biggest biotech players at CNBC
10:52AM  Keep an Eye on these 3 Biotech Stocks Zacks
10:00AM  Alexion Likely to Keep Earnings Streak Alive Zacks
10:00AM  Synageva Heading For Big Disappointment at Seeking Alpha
21-Apr-14 06:01PM  Here's What You Need to Know About Alexion Pharmaceuticals' Upcoming Earnings at Motley Fool
02:34PM  Biotech Is Not A Popping Bubble: Buy The Dip While You Can at Seeking Alpha
09:38AM  [video] Green on the screen at Nasdaq at CNBC
06:39AM  Is a Surprise Coming for Alexion Pharmaceuticals (ALXN) This Earnings Season? Zacks
18-Apr-14 12:12PM  Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings at Investor's Business Daily
17-Apr-14 06:32PM  How Are Orphan Drugmakers Faring in the Great Biotech Downturn? at Motley Fool
04:23PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of EDGAR Online
04:15PM  Alexion Announces the Appointment of John T. Mollen to Its Board of Directors Business Wire
06:51AM  What Falling Estimates & Price Mean for Discovery Laboratories (DSCO) Zacks
02:43AM  Transition Therapeutics (TTHI) Jumps: Stock Up 11.5% Zacks
16-Apr-14 09:07AM  Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data Zacks
15-Apr-14 04:15PM  FDA Nod for Merck's Grastek Zacks
14-Apr-14 05:32PM  Facebook, Walgreen Climb Monday On International News at Investor's Business Daily
04:20PM  Pipeline Progress at Coronado Biosciences Zacks
03:30PM  Positive Results on Intercept Pharma's OCA Zacks
10:30AM  Gilead Bucks Biotech Trend Thanks to Sovaldi News Zacks
11-Apr-14 07:05PM  IPO Frenzy Freezes As Four New Issues Fail To Debut Friday Investor's Business Daily
06:11PM  Researchers to Present New Data on Asfotase Alfa in Infants and Juveniles with Hypophosphatasia at the Joint Meeting of the Pediatric Academic Societies and the Asian Society for Pediatric Research Business Wire
03:54PM  Eight pricey stocks haunting the Nasdaq at Fortune
09:34AM  Market selloff: is this the beginning of a correction? Hot Stock Minute
08:58AM  STOCKS TO WATCH: JPM, WFC, HRB, GPS, ALXN, BIIB, NFLX Hot Stock Minute
07:54AM  Stock futures lower after J.P. Morgan earnings, Nasdaq's worst day since 2011; Is this the start of a correction? Hot Stock Minute
02:34AM  Rite Aid (RAD) Jumps: Stock Up 8.4% Zacks
10-Apr-14 08:04PM  Why Alexion Pharmaceuticals, Gilead Sciences, and Monster Beverage Corporation Are Todays 3 Worst Stocks at Motley Fool -7.49%
07:11PM  Nasdaq's worst swoons since 2011 puts investors on edge at USA TODAY
06:14PM  Nasdaq drops 3 percent, worst day since November 2011 Reuters
06:12PM  US STOCKS-Nasdaq drops 3 pct, worst day since November 2011 Reuters
05:05PM  Stocks Fall In Higher Volume; Alexion, Gilead Drop 7% at Investor's Business Daily
04:53PM  Nasdaq pummeled in worst day since 2011 as tech, biotech cave (Stock market live blog recap) at MarketWatch
04:49PM  Nasdaq marks worst day since November 2011 as biotechs sink Reuters
04:47PM  US STOCKS-Nasdaq marks worst day since Nov. 2011 as biotechs sink Reuters
04:12PM  Stock market live blog: Nasdaq pummelled in worst day since 2011 as tech, biotech cave at MarketWatch
03:41PM  Stock market live blog: Nasdaq dives 3% as biotech, Facebook, Google drop at MarketWatch
03:03PM  'Very Volatile' Biotech, in Chart Form at The Wall Street Journal
02:59PM  There Goes the Market: Dow Industrials Off 200 Points, Nasdaq Plunges 3% at Barrons.com
02:59PM  There Goes the Market: Dow Industrials Off 200 Points, Nasdaq plunges 3% at Barrons.com
02:33PM  Thursday Sector Laggards: Healthcare, Technology & Communications at Forbes
02:19PM  US STOCKS-Nasdaq has worst day since June 2012, weighed again by biotechs Reuters
01:55PM  Biotech hammered as ETFs down 5%, while some stocks fall 10% at MarketWatch
01:09PM  Oh Biotech, You Are a Cruel Bitch at TheStreet
12:58PM  Meet the poster child for momentum stock selloff at CNBC
10:00AM  Alexion Pharmaceuticals to Report First Quarter 2014 Results on Thursday, April 24, 2014 Business Wire
08:22AM  3 Top-Ranked Biotech Stocks on the Rebound Zacks
09-Apr-14 05:13PM  Nasdaq Up 1.7%; Bed, Bath & Beyond Sinks After Hours at Investor's Business Daily +5.55%
12:27PM  [video] The biotech parade at CNBC
08:02AM  Alexion, Biogen Among Leading Big-Cap Biotechs at Investor's Business Daily
08-Apr-14 03:41PM  A Sharp Pullback In Celldex Could Be A Window Of Opportunity at Seeking Alpha
11:10AM  Halozyme Falls on Phase II Study Halt Zacks
10:40AM  Bristol-Myers Seeks FDA Approval for HCV Candidates Zacks
09:26AM  RadNet Touches New 52-Week High Zacks
07:48AM  The Zacks Analyst Blog Highlights: Facebook, Tesla Motors, Amazon.com, Netflix and Alexion Pharmaceuticals Zacks
06:54AM  Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% Zacks
06:23AM  [$$] Nobody Expects a Spanish Disquistion at Barrons.com
07-Apr-14 05:25PM  Tweet of the Week: Big Biotech Dominates Industry Gains at Motley Fool
12:23PM  Momentum Slide to Continue for Netflix, Facebook? Zacks
09:41AM  $5.6 Billion Questcor Deal Means High Drug Prices For Everybody at Forbes
06:26AM  Exact Sciences Corporation (EXAS) in Focus: Stock Up 5.73% Zacks
04-Apr-14 02:43PM  Investors continue to pour out of biotech holdings at MarketWatch -5.92%
07:05AM  Weakness Seen in Kindred Biosciences (KIN): Stock Tumbles 9.0% Zacks
03-Apr-14 05:20PM  Good News for Keryx Zacks
05:15PM  Glaxo Stops MAGE-A3 Lung Cancer Study Zacks
04:50PM  ZIOPHARM Upgraded to Strong Buy Zacks
03:55PM  Encouraging Results on Gilead's Sovaldi Zacks
01:27PM  S&P 500 Edges Lower As Biotech Selling Weighs On Nasdaq at Investor's Business Daily
07:49AM  Myriad Genetics (MYGN) Worth Watching: Stock Rises 11.5% Zacks
07:21AM  What Falling Estimates & Price Mean for bluebird bio (BLUE) Zacks
06:45AM  Should You Get Rid of Synageva BioPharma (GEVA) Now? Zacks
02-Apr-14 04:55PM  Eli Lilly Signs Deal with Prasco Zacks
03:30PM  FDA Panel Positive on MannKind's Afrezza Zacks
10:30AM  Encouraging Data on Sanofi/Regeneron's Alirocumab Zacks
02:06AM  TetraLogic Pharmaceuticals (TLOG) Soars: Stock Up 20.7% Zacks
01:54AM  Durata Therapeutics (DRTX) in Focus: Stock Up 5.64% Zacks
01-Apr-14 03:45PM  Bayer's Adempas Cleared in the EU Zacks
02:15PM  Oxygen Biotherapeutics Up on FDA News Zacks
01:03PM  3 Stocks Advancing The Health Care Sector at TheStreet
10:30AM  Cubist Rises on Favorable FDA Panel View Zacks
01:43AM  Cara Therapeutics Inc. (CARA) Worth Watching: Stock Surges 12.7% Zacks
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MADRI JOSEPH ADirectorMar 11Option Exercise9.5160,000570,600239,217Mar 13 05:03 PM
MADRI JOSEPH ADirectorMar 11Sale178.6160,00010,716,300179,217Mar 13 05:03 PM
Carmichael ClareSVP, Chief HR OfficerMar 03Sale174.7730553,30516,760Mar 04 05:35 PM
PARVEN ALVIN SDirectorFeb 11Sale174.062,471430,1024,840Feb 13 05:00 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerFeb 10Sale167.311,635273,552101,308Feb 10 06:47 PM
MADRI JOSEPH ADirectorFeb 07Option Exercise4.9330,000147,900209,217Feb 10 06:46 PM
Sinha VikasEVP & CFOFeb 07Sale155.571,620252,029137,900Feb 10 06:46 PM
Moriarty John BSVP & General CounselFeb 07Sale155.601,036161,19822,232Feb 10 06:46 PM
MADRI JOSEPH ADirectorFeb 07Sale159.0030,0004,770,000179,217Feb 10 06:46 PM
Wright Frank JSVP, President Alxn Pharm IntlFeb 07Sale155.571,098170,81919,670Feb 10 06:48 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerFeb 07Sale155.571,620252,030102,943Feb 10 06:47 PM
Hallal DavidEVP, Chief Commercial OfficerFeb 07Sale155.571,610250,461113,965Feb 10 06:47 PM
BELL LEONARDCEOFeb 07Sale155.564,620718,672986,696Feb 10 06:48 PM
Carmichael ClareSVP, Chief HR OfficerFeb 07Sale155.561,006156,49613,765Feb 10 06:48 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerFeb 06Option Exercise93.833,800356,55498,618Feb 10 06:47 PM
Hallal DavidEVP, Chief Commercial OfficerFeb 06Sale156.95101,570113,965Feb 10 06:47 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerFeb 06Sale155.113,800589,41894,818Feb 10 06:47 PM
Sinha VikasEVP & CFOFeb 04Sale153.632,700414,801129,775Feb 05 07:57 PM
BELL LEONARDCEOFeb 04Sale153.638,8701,362,698963,276Feb 05 07:56 PM
Carmichael ClareSVP, Chief HR OfficerFeb 04Sale153.63760116,7598,703Feb 05 07:56 PM
Hallal DavidEVP, Chief Commercial OfficerFeb 04Sale153.632,390367,176105,830Feb 05 07:56 PM
MATHIS LARRYDirectorFeb 03Option Exercise23.5580,7291,901,540110,185Feb 05 07:57 PM
LINK MAXDirectorFeb 03Sale155.1640,0006,206,21958,574Feb 05 07:57 PM
Sinha VikasEVP & CFOFeb 03Sale157.14852133,883132,475Feb 05 07:57 PM
MATHIS LARRYDirectorFeb 03Sale157.5080,72912,714,58629,456Feb 05 07:57 PM
BELL LEONARDCEOFeb 03Sale157.142,920458,849972,146Feb 05 07:56 PM
Hallal DavidEVP, Chief Commercial OfficerFeb 03Sale157.14729114,555108,220Feb 05 07:56 PM
BELL LEONARDCEOJan 29Sale133.812,660355,929975,066Jan 31 05:29 PM
Sinha VikasEVP & CFOJan 29Sale133.43994132,633133,327Jan 31 05:29 PM
Hallal DavidEVP, Chief Commercial OfficerJan 29Sale133.4572997,283108,949Jan 31 05:29 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerJan 29Sale133.311,118149,039103,068Jan 31 05:30 PM
BELL LEONARDCEOJan 22Option Exercise10.2912,817131,887990,543Jan 22 05:52 PM
BELL LEONARDCEOJan 22Sale141.4112,8171,812,397977,726Jan 22 05:52 PM
BELL LEONARDCEOJan 21Option Exercise8.19110,930908,0651,137,409Jan 22 05:52 PM
BELL LEONARDCEOJan 21Sale140.91110,93015,631,693977,726Jan 22 05:52 PM
BELL LEONARDCEOJan 17Option Exercise6.9032,689225,5541,076,351Jan 22 05:52 PM
BELL LEONARDCEOJan 17Sale140.2032,6894,582,8661,043,662Jan 22 05:52 PM
BELL LEONARDCEOJan 13Option Exercise6.9015,845109,3311,059,507Jan 15 06:19 PM
BELL LEONARDCEOJan 13Sale135.2515,8452,143,0361,043,662Jan 15 06:19 PM
BELL LEONARDCEOJan 10Option Exercise6.9011,70580,7651,043,662Jan 10 05:26 PM
BELL LEONARDCEOJan 10Sale135.0011,7051,580,1751,031,957Jan 10 05:26 PM
BELL LEONARDCEOJan 09Option Exercise6.901,0397,1691,032,996Jan 10 05:26 PM
BELL LEONARDCEOJan 09Sale135.051,039140,3171,031,957Jan 10 05:26 PM
BELL LEONARDCEOJan 08Option Exercise5.426,41134,7761,038,368Jan 10 05:26 PM
BELL LEONARDCEOJan 08Sale134.936,411865,0361,031,957Jan 10 05:26 PM
BELL LEONARDCEODec 19Option Exercise5.1835,000181,3001,066,957Dec 20 04:24 PM
BELL LEONARDCEODec 19Sale129.9035,0004,546,5001,031,957Dec 20 04:24 PM
Hallal DavidEVP, Chief Commercial OfficerDec 18Option Exercise17.987,295131,164116,973Dec 20 04:25 PM
Sinha VikasEVP & CFODec 18Option Exercise17.6532,026565,259166,347Dec 20 04:24 PM
BELL LEONARDCEODec 18Option Exercise5.62145,664818,5701,171,957Dec 20 04:24 PM
BELL LEONARDCEODec 18Sale125.49140,00017,569,1491,031,957Dec 20 04:24 PM
Sinha VikasEVP & CFODec 18Sale127.8132,0264,093,243134,321Dec 20 04:24 PM
Hallal DavidEVP, Chief Commercial OfficerDec 18Sale127.6115,3631,960,472109,678Dec 20 04:25 PM
Hallal DavidEVP, Chief Commercial OfficerDec 18Sale127.537,295930,331109,678Dec 20 04:25 PM
Hallal DavidEVP, Chief Commercial OfficerDec 09Option Exercise17.9814,637263,173124,315Dec 11 08:56 PM
Hallal DavidEVP, Chief Commercial OfficerDec 09Option Exercise17.9810,705192,476120,383Dec 11 08:56 PM
Sinha VikasEVP & CFODec 09Option Exercise17.6517,974317,241152,295Dec 11 08:56 PM
Sinha VikasEVP & CFODec 09Sale127.6617,9742,294,561134,321Dec 11 08:56 PM
Hallal DavidEVP, Chief Commercial OfficerDec 09Sale127.6314,6371,868,120109,678Dec 11 08:56 PM
Hallal DavidEVP, Chief Commercial OfficerDec 09Sale127.6310,7051,366,279109,678Dec 11 08:56 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerNov 04Option Exercise31.6414,125446,963118,311Nov 05 06:50 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerNov 04Sale123.8714,1251,749,664104,186Nov 05 06:50 PM
Sinha VikasEVP & CFOOct 28Option Exercise17.6550,000882,500360,808Oct 30 06:00 PM
Hallal DavidEVP, Chief Commercial OfficerOct 28Option Exercise17.9830,000539,400118,178Oct 30 06:00 PM
Hallal DavidEVP, Chief Commercial OfficerOct 28Option Exercise17.9818,000323,640106,178Oct 30 06:00 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 28Option Exercise81.7240,0373,271,739145,223Oct 30 05:59 PM
Hallal DavidEVP, Chief Commercial OfficerOct 28Sale123.0530,0003,691,50488,178Oct 30 06:00 PM
Hallal DavidEVP, Chief Commercial OfficerOct 28Sale123.0518,0002,214,90188,178Oct 30 06:00 PM
Sinha VikasEVP & CFOOct 28Sale122.9750,0006,148,255310,808Oct 30 06:00 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 28Sale123.891,000123,890104,186Oct 30 05:59 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 28Sale124.0740,0374,967,340105,186Oct 30 05:59 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerSep 24Sale112.5430434,212105,186Sep 26 04:59 PM
MADRI JOSEPH ADirectorSep 16Option Exercise5.5530,000166,500209,217Sep 18 05:00 PM
MADRI JOSEPH ADirectorSep 16Sale115.0030,0003,450,000179,217Sep 18 05:00 PM
BELL LEONARDCEOSep 16Sale115.003,500402,5001,026,293Sep 18 05:00 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerSep 13Sale114.371,000114,370105,490Sep 17 06:09 PM
BELL LEONARDCEOSep 04Sale110.071,850203,6301,001,669Sep 06 05:11 PM
BELL LEONARDCEOSep 03Sale110.2130,6583,378,8901,003,519Sep 03 06:11 PM
Carmichael ClareSVP, Chief HR OfficerAug 30Sale107.581,237133,0759,463Sep 03 06:11 PM
BELL LEONARDCEOAug 30Sale109.9250054,9601,034,177Sep 03 06:11 PM
BELL LEONARDCEOAug 29Sale109.931,992218,9811,034,677Sep 03 06:11 PM
BELL LEONARDCEOAug 16Sale105.2554,5485,740,9241,036,669Aug 16 05:54 PM
BELL LEONARDCEOAug 15Sale106.6285,4529,110,8471,091,217Aug 16 05:54 PM
Hallal DavidEVP, Chief Commercial OfficerAug 05Sale116.8773085,31588,178Aug 07 05:26 PM
Sinha VikasEVP & CFOAug 05Sale116.8785299,573310,808Aug 07 05:26 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerAug 05Sale116.8785299,573106,490Aug 07 05:27 PM
BELL LEONARDCEOAug 05Sale116.872,919341,1441,176,669Aug 07 05:27 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerAug 02Option Exercise31.6414,125446,963121,467Aug 02 05:02 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerAug 02Sale115.3314,1251,629,018107,342Aug 02 05:02 PM
Sinha VikasEVP & CFOJul 30Sale110.86995110,306311,660Aug 01 05:04 PM
Hallal DavidEVP, Chief Commercial OfficerJul 30Sale110.8674682,70288,908Aug 01 05:04 PM
BELL LEONARDCEOJul 30Sale114.62212,73724,384,0371,179,588Aug 01 05:04 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerJul 30Sale110.861,120124,163107,342Aug 01 05:04 PM
Hallal DavidEVP, Chief Commercial OfficerJul 12Option Exercise17.6550,000882,500139,654Jul 16 04:44 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerJul 12Option Exercise21.0218,000378,370126,462Jul 16 04:47 PM
Sinha VikasEVP & CFOJul 12Option Exercise13.3550,000667,648362,655Jul 16 04:48 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerJul 12Sale119.9018,0002,158,200108,462Jul 16 04:47 PM
Sinha VikasEVP & CFOJul 12Sale120.0050,0006,000,000312,655Jul 16 04:48 PM
Hallal DavidEVP, Chief Commercial OfficerJul 12Sale120.0050,0006,000,00089,654Jul 16 04:44 PM
SQUINTO STEPHEN PEVP, Global Ops. OfficerJul 01Option Exercise39.1344,1251,726,763152,587Jul 03 04:49 PM